Apolipoprotein A inhib 
Welcome,         Profile    Billing    Logout  
 5 Companies  3 Products   3 Products   9 Diseases   7 Trials   398 News 


12345»
  • ||||||||||  Journal:  Spontaneous reperfusion in STEMI: Its mechanisms and possible modulation. (Pubmed Central) -  Mar 17, 2024   
    or glycoprotein IIb/IIIa inhibitors, oral factor XIa inhibitors, interleukin-6 inhibitors, and apolipoprotein(a) antisense oligonucleotides in patients with cardiovascular disease are ongoing. Future studies will be needed to determine the impact of these novel antithrombotic, anti-inflammatory and lipid lowering therapies on endogenous fibrinolysis and spontaneous reperfusion.
  • ||||||||||  pelacarsen (AKCEA-APO(a)-LRx) / Ionis, Novartis
    Review, Journal:  Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. (Pubmed Central) -  Oct 29, 2021   
    Phase 2 clinical trials have shown that the antisense oligonucleotide pelacarsen reduced mean Lp(a) levels by 80%, allowing 98% of subjects to reach on-treatment levels of <125 nmol/l (∼50 mg/dl)...Additional ribonucleic acid-targeted therapies to lower Lp(a) are in preclinical and clinical development. The testing of the Lp(a) hypothesis will provide proof whether Lp(a)-mediated risk can be abolished by potent Lp(a) lowering.
  • ||||||||||  Journal, Epigenetic controller:  DNA methylation profiling identifies a high effect genetic variant for lipoprotein(a) levels. (Pubmed Central) -  Jun 3, 2021   
    This association is due to an uncommon, but highly effective genetic variant, which was not in significant linkage disequilibrium with other variants known to influence Lp(a) levels or apo(a) isoform size. This study highlights the utility of CpG site methylation to identify potentially important genetic associations that would not be readily apparent in a comparable size genetic association study.
  • ||||||||||  Angeliq (drospirenone/estradiol) / Bayer
    Journal:  Menopausal hyperinsulinism and hypertension - new approach. (Pubmed Central) -  May 28, 2021   
    Of 24 h day blood pressure decreased significantly. E2/DRSP represents suitable therapy for hyperinsulinemic, grade I hypertensive menopausal women with typical symptoms and normal weight.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Statin therapy increases lipoprotein(a) levels. (Pubmed Central) -  May 15, 2021   
    This meta-analysis reveals that statins significantly increase plasma Lp(a) levels. Elevations of Lp(a) post-statin therapy should be studied for effects on residual cardiovascular risk.
  • ||||||||||  Journal:  DNA-Mediated Stack Formation of Nanodiscs. (Pubmed Central) -  May 11, 2021   
    The direct disulphide bond formation of nanodiscs formed by the MSP1D1_N42C variant led to dimers and trimers with low yield. In contrast, transmission electron microscopy revealed that the attachment of oligonucleotides to the engineered cysteines of MSP1D1 allowed the growth of submicron-sized tracts of stacked nanodiscs through the hybridization of nanodisc populations carrying complementary strands and a flexible spacer.
  • ||||||||||  Preclinical, Journal:  Scutellarin regulates osteoarthritis in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) -  May 6, 2021   
    The protein expression levels of AKT, phosphorylated (p)-AKT, mTOR and p-mTOR in the PI3K/AKT/mTOR signaling pathway were decreased in the IL-1β-induced SW1353 cells following scutellarin treatment. Overall, the findings of the present study demonstrated that scutellarin regulated OA in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
  • ||||||||||  Clinical, Journal:  The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. (Pubmed Central) -  Apr 16, 2021   
    After multiple testing correction, statistically significant interactions between time and group were observed for the primary endpoint glycemia (β = 0.36, p < 0.0001) and for the secondary endpoints HDL (β = -0.10, p < 0.0001), total cholesterol/HDL (β = 0.27, p < 0.0001), LDL (β = 0.15, p = 0.005), LDL/HDL (β = 0.23, p = 0.001), insulin (β = 1.28, p = 0.04), glycated hemoglobin (β = 0.21, p = 0.0002), A1c-derived average glucose (β = 0.34, p = 0.0002), ApoB (β = 6.00, p = 0.01), ApoA (β = -4.50, p = 0.04), ApoB/ApoA (β = 0.08, p = 0.003), waist circumference (β = 1.89, p = 0.05), VATβ = 222.37, p = 0.005). In conclusion, these results confirm that Cs supplementation has a significant effect on metabolic parameters in IFG patients.
  • ||||||||||  Journal:  Molecular Evolution of Apolipoprotein Multigene Family and the Original Functional Properties of Serum Apolipoprotein (LAL2) in Lampetra japonica. (Pubmed Central) -  Apr 13, 2021   
    Moreover, LAL2 was found to recognize and bind to gram-positive bacteria (Staphylococcus aureus and Bacillus cereus) and gram-negative bacteria (Escherichia coli) and play an important role in the antibacterial process. All in all, our data reveals a long, complex evolutionary history for apolipoprotein genes under different selection pressures, confirms the immune effect of LAL2 in lamprey sera against pathogens, and lays the foundation for further research regarding biological functions of lamprey immune systems.
  • ||||||||||  Journal:  ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. (Pubmed Central) -  Mar 24, 2021   
    These findings identify somatic mutations in ABCA1 that subvert its anti-proliferative and cholesterol efflux functions and permit the progression of myeloid neoplasms. Therapeutic increases in HDL bypass these defects and restore normal hematopoiesis.
  • ||||||||||  Clinical, Journal:  When do paediatric patients with familial hypercholesterolemia need statin therapy? (Pubmed Central) -  Mar 23, 2021   
    Therapeutic increases in HDL bypass these defects and restore normal hematopoiesis. Increased risk of cardiovascular events based on ApoB/ApoA index and carotid e-tracking or IMT examination in paediatric patients with FH is an indication for statin therapy initiation.
  • ||||||||||  Retrospective data, Review, Journal:  Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Feb 27, 2021   
    Treatment of overt but not subclinical hyperthyroidism is associated with worsening of the lipid profile. Levothyroxine therapy in both overt and subclinical hypothyroidism leads to improvement in the lipid profile, with a smaller magnitude of improvement in subclinical hypothyroidism.
  • ||||||||||  Clinical, Journal:  Association Between Serum Lipid Levels and Patients With Primary Angle-Closure Glaucoma in China: A Cross Sectional, Case-Control Study. (Pubmed Central) -  Feb 20, 2021   
    Logistic regression analyses showed that high serum HDL-C (odds ratio [OR] = 11.01, 95% CI = 5.616-21.587), LDL-C (OR = 1.330, 95% CI = 1.079-1.640), SDLDL-C (OR = 1.007, 95% CI = 1.005-1.008), APOA (OR = 13.621, 95% CI = 7.251-25.591), APOB (OR = 2.243, 95% CI = 1.060-4.732), LPa (OR = 0.999, 95% CI = 0.998-1.00), and CHOL (OR = 1.131, 95% CI = 1.005-1.326) levels were significantly associated with PACG. High serum HDL-C, LDL-C, APOA, APOB, LPa, and CHOL levels were associated with PACG.
  • ||||||||||  Review, Journal:  Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives. (Pubmed Central) -  Feb 16, 2021   
    Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies...In patients with concomitant elevations of Lp[a] and LDL, either combining the two apo[a] and apoB antisense therapies (a strategy which has never been tested), or the combination of well-known and relatively inexpensive drugs such as statins with antisense apo[a] inhibitors can be theoretically suggested. The results of an upcoming phase 3 study with antisense apo[a] inhibitors will hopefully provide definitive clues as to whether this approach may become the standard of care in patients with increased Lp[a] concentrations.
  • ||||||||||  Journal:  Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease. (Pubmed Central) -  Jan 31, 2021   
    Lp(a), C-reactive protein, circulating immune complexes, and neutrophil-to-lymphocyte ratio are associated with the stenotic atherosclerosis of different vascular beds. Lp(a) levels increase and IgM autoantibodies to Lp(a) decrease with the number of affected vascular beds.
  • ||||||||||  Clinical, Observational data, Journal:  The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study. (Pubmed Central) -  Jan 26, 2021   
    The above indicators were reviewed after 3 months of treatment.There were no statistically significant differences of age, gender, blood pressure, incidence of type 2 diabetes mellitus, fasting blood glucose, folic acid, homocysteine, Lp-PLA2, total cholesterol, 3 acyl glycerin, apolipoprotein B, lipoprotein (a), high density lipoprotein cholesterol, and low density lipoprotein cholesterol were found among 3 groups (P > .05); however, after being treated for 3 months, there was statistically significant difference in folic acid among 3 groups (P < .05), there was statistically significant difference in apolipoprotein A between Group A and Group B (t = 0.505, P = .039), and also between Group A and Group C (t = 0.052, P = .017). There were statistically significant differences in Lp-PLA2 (t = 24.320, P = .016) and systolic blood pressure variability (t = 0.154, P = .018) between Group A and Group C.For CHD patients with hyperhomocysteinemia, the higher dose (0.8 mg) of folic acid supplement was beneficial for increasing the apolipoprotein A, reducing the Lp-PLA2, and improving the systolic blood pressure variation, which might help to improve the prognosis in these patients.
  • ||||||||||  Clinical, Journal:  The metabolomic signatures of alcohol consumption in young adults. (Pubmed Central) -  Jan 13, 2021   
    Associations with metabolites were similar for total and types of alcohol. Alcohol consumption in young adults is related to a diverse range of metabolomic signatures associated with benefits and harms to health.
  • ||||||||||  Journal:  Lipoprotein(a) and Cardiovascular Diseases　- Revisited. (Pubmed Central) -  Dec 16, 2020   
    Although conventional pharmacological therapies, such as statin, niacin, and cholesteryl ester transfer protein, have failed to significantly reduce Lp(a) levels, emerging new therapeutic strategies using proprotein convertase subtilisin-kexin type 9 inhibitors or antisesnse oligonucleotide technology have shown promising results in effectively lowering Lp(a). In this review we discuss the revisited important role of L(a) and strategies to overcome residual risk in the statin era.
  • ||||||||||  Clinical, Journal:  Predictors of Coronary Plaque Vulnerability in Patients with Stable Coronary Artery Disease (Pubmed Central) -  Nov 27, 2020   
    Correlation analysis showed a negative correlation between the level of high-density lipoproteins (HDL) and calcium volume (r= -0.4104; р=0.023); a positive correlation between the blood glucose level as determined by the oral glucose tolerance test and the lipid component (r=0.48198; р=0.033); and a negative correlation between the apolipoprotein A level and the calcium volume (r= -0.4297; р=0.008).Conclusion      The study demonstrated a high prevalence of vulnerable plaques in nontarget coronary arteries in patients with sIHD. In this process, dyslipidemia indexes (LDL, apolipoproteins A) correlate with the calcium volume whereas blood glucose, as measured in the oral glucose tolerance test, correlates with the lipid component of coronary plaque.